drugset / Trial / NCT05001698
Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To assess the pharmacokinetic parameters of anifrolumab in Chinese participants with active systemic lupus erythematosus(SLE).
Timeline
- Start
- 2021-07-27
- Primary completion
- 2022-06-02
- Completion
- 2022-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anifrolumab | Monoclonal antibody | — | Intravenous |